Results

1–10 of 15 results for vision loss

Intravitreal Avacincaptad Pegol in Geographic Atrophy: Post-Hoc Analysis of Vision Loss From the GATHER Clinical Program
Carl J Danzig, MD
Annual Meeting Talks
2023
Multiwavelength Photobiomodulation Significantly Reduces Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration
Eleonora Lad, MD, PhD
Annual Meeting Talks
2024
Baseline Characteristics Associated With Catastrophic Vision Loss Due to Subretinal Hemorrhage in Patients Undergoing Treatment for Neovascular Macular Degeneration
Eric W Schneider, MD
Annual Meeting Talks
2024
Multiwavelength Photobiomodulation Significantly Reduces Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration
Eleonora Lad, MD, PhD
Updates from the Field
2024
Acute Vision Loss in a 66-Year-Old White Female: A Diagnostic and Therapeutic Challenge
On Demand Cases, Courses, and Papers
2022
Effects of the Mitochondria-Targeted Drug Elamipretide on Leakage-Independent Vision Loss in Fellow Eyes with Neovascular AMD in the ReCLAIM Study
Priyatham (Prithu) S Mettu, MD
Updates from the Field
2019
Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen
Michael J Allingham, MD, PhD
Annual Meeting Talks
2019
Mitochondria-Targeted Drug Elamipretide for Treatment of Vision Loss in Dry AMD With Noncentral Geographic Atrophy
Scott W. Cousins, MD
Annual Meeting Talks
2019
Vision Loss in a Patient With Primary Pulmonary Hypertension and Long-Term Use of Sildenafil
Christina Y Weng, MD, MBA, FASRS
Annual Meeting Talks
2016
“Real World” U.S. Outcomes of Anti-VEGF Therapy in Neovascular AMD: Risk of Vision Loss is Greatest in Patients with Better Baseline Visual Acuity
Thomas A. Ciulla, MD, MBA, FASRS
Annual Meeting Talks
2016